Improving outcomes in KRAS-mutant pancreatic cancer

preview_player
Показать описание
John H. Strickler, MD, Duke Cancer Institute, Durham, NC, discusses the use of sotorasib and KRAS inhibitors in pancreatic cancer, as well as potential combinations to improve outcomes in KRAS-mutant patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
  1. VJOncology
  2. Speaker: John Strickler
  3. Institution: Duke Cancer Institute
  4. Event: ASCO 2022
  5. Format: Interview
  6. Subject: Gastrointestinal Cancer
Рекомендации по теме
Improving outcomes in 0:00:41

Improving outcomes in KRAS-mutant pancreatic cancer

Personalized treatment approaches 0:00:51

Personalized treatment approaches for patients with KRAS-mutant pancreatic cancer

Treatment strategies for 0:01:37

Treatment strategies for KRAS-mutant NSCLC with co-mutations

Voice of Pancreatic 0:45:20

Voice of Pancreatic Cancer Podcast - Targeting the KRAS mutation for more effective cancer treatment

How to improve 0:26:09

How to improve on the outcome in RAS mutant tumors

GRAND ROUNDS: Improving 0:44:34

GRAND ROUNDS: Improving Outcomes in Pancreatic Cancer 120419

Sotorasib outperforms docetaxel 0:02:59

Sotorasib outperforms docetaxel in previously treated KRAS-mutated NSCLC | Melissa Johnson

Advances in the 0:01:27

Advances in the development of KRAS inhibitors

Improving Outcomes in 1:02:02

Improving Outcomes in Molecularly Altered NSCLC Through Precision Testing and Treatment

KRAS G12C inhibitors 0:00:58

KRAS G12C inhibitors for GI cancer

Dr. Mark Girgis: 0:22:26

Dr. Mark Girgis: Pancreatic Cancer Progress Report: Where Are We?

Mutant p53 and 0:05:17

Mutant p53 and oncogenic KRAS drive metastasis in pancreatic cancer

Personalized therapies for 0:07:46

Personalized therapies for patients with KRAS-mutant lung cancer

Improving Outcomes in 1:02:08

Improving Outcomes in Molecularly Altered NSCLC Through Precision Testing and Treatment

Current treatment strategies 0:01:10

Current treatment strategies KRASG12C–mutated NSCLC

The potential of 0:10:34

The potential of KRAS inhibitors for non-small-cell lung cancer

Dr. Skoulidis and 1:56:56

Dr. Skoulidis and Terri Conneran Discuss Treatment Strategy for Lung, Colon, and Pancreatic Cancers

Future targets for 0:01:10

Future targets for pancreatic cancer treatment

KRAS Driven Cancers 0:00:41

KRAS Driven Cancers (KRAS episode 2)

Study shows promise 0:03:37

Study shows promise of new anti-KRAS drug for pancreatic cancer

ASCO 2022: Efficacy 0:01:07

ASCO 2022: Efficacy of adapted physical activity in patients with pancreatic cancer

What is a 0:01:11

What is a KRAS mutation?

Innovative Approaches to 0:31:44

Innovative Approaches to Investigating KRAS Therapeutics with Biochemical and Cell Based Assays 2

Navigating Pancreatic Cancer 1:00:31

Navigating Pancreatic Cancer - New Approaches and Targeting KRAS (John Strickler, MD)